How Ipamorelin Affects Prolactin

Prolactin elevation from GHRPs is a class effect of compounds that non-selectively activate GHS-R1a receptors in lactotrophs or hypothalamic dopaminergic neurons. Ipamorelin avoids this through receptor selectivity:

1. Ipamorelin's GHS-R1a selectivity: Ipamorelin was designed to activate GHS-R1a on pituitary somatotrophs with high selectivity, avoiding significant activation of GHS-R1a in the hypothalamus, corticotrophs, and lactotrophs. This selective pituitary somatotroph action confines its effects to GH release without collateral hormonal disruption.
2. GHRP-6 and prolactin: GHRP-6 activates GHS-R1a more broadly across pituitary cell types. Lactotroph GHS-R1a activation can directly stimulate prolactin secretion. Additionally, GHS-R1a activation in hypothalamic neurons that regulate dopamine tone can reduce dopamine-mediated prolactin inhibition, further raising prolactin.
3. Raun et al. (1998, PMID 9849822) confirmation: This pivotal dose-escalation study in pigs tested ipamorelin versus GHRP-6 and GHRP-2 across a wide dose range. At doses up to 200 times the effective GH-releasing dose, ipamorelin produced no significant change in prolactin. GHRP-6 at equivalent doses produced significant prolactin elevation. This established prolactin selectivity as a defining pharmacological advantage of ipamorelin.
4. Clinical significance in the PED context: Male AAS users already have elevated estradiol risk, which combined with prolactin elevation substantially increases gynecomastia risk and libido suppression. Choosing ipamorelin over non-selective GHRPs removes the prolactin component of this risk.

Standard ipamorelin protocol (200-300 mcg SC, 1-2 times daily):

• Serum prolactin: no significant change expected; normal male range approximately 2 to 14 ng/mL
• No prolactin-related side effects: no additive gynecomastia risk, no libido suppression from prolactin

Confirmed by Raun et al. (1998):

• Ipamorelin at 200x effective GH dose: no significant prolactin change
• GHRP-6 at equivalent doses: significant prolactin elevation
• GHRP-2: intermediate prolactin elevation, less than GHRP-6

Combined CJC-1295 no-DAC plus ipamorelin:

• Both components are prolactin-neutral; combined protocol maintains zero prolactin effect

Routine prolactin monitoring is not required for ipamorelin-only or ipamorelin plus CJC-1295 no-DAC protocols.

When to check prolactin:

• If gynecomastia or galactorrhoea appears in the absence of prolactin-elevating compounds. These symptoms while on ipamorelin alone almost certainly have another driver.
• When transitioning from GHRP-6 or hexarelin: check prolactin at transition and 4 to 6 weeks post-switch to confirm normalisation.
• Annual comprehensive hormone panel including prolactin is good practice for long-term peptide users, not because ipamorelin causes changes.

No prolactin-specific management is required for ipamorelin.

If elevated prolactin is detected on ipamorelin:

• Investigate nandrolone, trenbolone, antipsychotics, antidepressants, hypothyroidism, prolactinoma, and significant physical or emotional stress before attributing to ipamorelin
• Ipamorelin is essentially excluded as a driver of prolactin elevation by the Raun 1998 data

Transitioning from GHRP-6 to ipamorelin:

• Prolactin typically normalises within 2 to 4 weeks of stopping GHRP-6
• Gynecomastia driven by GHRP-6-induced prolactin may improve once prolactin normalises, but requires concurrent estradiol management from AAS use
• Cabergoline 0.25 mg twice weekly is used to treat residual GHRP-6-induced hyperprolactinaemia during the transition period if symptomatic